Destroy Pancreatic Cancer   Report issue

Foundation Phase 2
Founded: Atlanta GA United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03797443
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Destroy Pancreatic Cancer

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4